NM-404 AS AN IMAGING AGENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States today. Accurate preoperative assessment of local, regional and distant metastatic spread is criticial for optimal management. Positron emission tomography scanning is a more sensitive technique for identifying mediastinal nodal metastases, but is more expensive and is not available everwhere. To develop a sensitive, more readily available imaging test, we will explore a carrier molecule deliver a radiopharmaceutical proble to the desired target tissue. To do this, we will use on radioiodinated phospholipid ether analogs (PLE) as potential diagnostic imaging agents. The PLE's are selectively retained in tumor membranes due to their inability to become metabolized and cleared. In preclinical studies, we have shown these molecules have high levels of selective accumulation in a wide variety of murine and human tumors including a human NSCLC model (A549) in SCID mice. The study may: (1) Determine the optimal imaging characteristics of radiolabelled I-131 NM-404 in ten patients with NSCLC. The pharmacokinetics, radiation dosimetry, biodistribution, and optimal imaging times will be determined. (2) Determine the specific tumor accumulation and metabolic fate of NM-404 in NSCLC tumors collected in five patients undergoing resection. (3) Collect preliminary data on imaging NSCLC tumors in ten patients with disease that can be evaluated.